FN2 Earnings Intelligence
TG Therapeutics, Inc. ratios (quarterly)
TG Therapeutics, Inc. (TGTX) Ratios (quarterly) derived from persisted SEC financial facts.
Key Stats
USD in millions, except per-share values and percentages.
| Metric | 3/31/2025 | 6/30/2025 | 9/30/2025 | 3/31/2026 | 9/30/2026 | 12/30/2026 est. | 3/30/2027 est. |
|---|---|---|---|---|---|---|---|
| Market Cap | - | - | - | - | - | - | - |
| - Cash | $132.1 | $129.1 | $74.1 | $442.2 | $429.4 | - | - |
| + Debt | - | - | - | - | - | - | - |
| Enterprise Value | - | - | - | - | - | - | - |
| Revenue | $120.9 | $141.1 | $161.7 | $204.9 | $259.9 | $290.2 | $293.9 |
| % Growth | 90.4% | 92.1% | 92.8% | 69.6% | 60.7% | - | 43.4% |
| Gross Profit | $105.3 | $122.2 | $133.6 | $171.4 | $217.9 | - | - |
| % Margin | 87.1% | 86.6% | 82.6% | 83.6% | 83.8% | - | - |
| EBITDA | $8.6 | - | - | $34.8 | - | - | - |
| % Margin | 7.1% | - | - | 17.0% | - | - | - |
| Net Income | $5.1 | $28.2 | $390.9 | $19.8 | $55.5 | - | - |
| % Margin | 4.2% | 20.0% | 241.7% | 9.7% | 21.3% | - | - |
| Diluted EPS | $0.03 | $0.17 | $2.43 | $0.12 | $0.35 | $0.52 | $0.64 |
| % Growth | - | 325.0% | 12,050.0% | 300.0% | -85.6% | - | 433.3% |
| Operating Cash Flow | -$28.7 | - | - | -$17.9 | - | - | - |
| CapEx | $0 | - | - | $0.1 | - | - | - |
| Free Cash Flow | -$28.7 | - | - | -$17.9 | - | - | - |
Historical market capitalization is not persisted, so Market Cap and Enterprise Value remain unavailable rather than mixing today's market value into prior periods.
Income Statement
USD in millions, except per-share values and percentages.
| Metric | 3/31/2025 | 6/30/2025 | 9/30/2025 | 3/31/2026 | 9/30/2026 | 12/30/2026 est. | 3/30/2027 est. |
|---|---|---|---|---|---|---|---|
| Revenue | $120.9 | $141.1 | $161.7 | $204.9 | $259.9 | $290.2 | $293.9 |
| Gross Profit | $105.3 | $122.2 | $133.6 | $171.4 | $217.9 | - | - |
| EBITDA | $8.6 | - | - | $34.8 | - | - | - |
| Net Income | $5.1 | $28.2 | $390.9 | $19.8 | $55.5 | - | - |
| Diluted EPS | $0.03 | $0.17 | $2.43 | $0.12 | $0.35 | $0.52 | $0.64 |
Balance Sheet
USD in millions, except per-share values and percentages.
| Metric | 3/31/2025 | 6/30/2025 | 9/30/2025 | 3/31/2026 | 9/30/2026 |
|---|---|---|---|---|---|
| Cash & Equivalents | $132.1 | $129.1 | $74.1 | $442.2 | $429.4 |
| Short-term Debt | - | - | - | - | - |
| Long-term Debt | $244.7 | $245 | $245.3 | $745.1 | $745.6 |
| Total Debt | - | - | - | - | - |
Cash Flow
USD in millions, except per-share values and percentages.
| Metric | 3/31/2025 | 6/30/2025 | 9/30/2025 | 3/31/2026 | 9/30/2026 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$28.7 | - | - | -$17.9 | - |
| Capital Expenditure | $0 | - | - | $0.1 | - |
| Free Cash Flow | -$28.7 | - | - | -$17.9 | - |
Ratios
USD in millions, except per-share values and percentages.
| Metric | 3/31/2025 | 6/30/2025 | 9/30/2025 | 3/31/2026 | 9/30/2026 |
|---|---|---|---|---|---|
| Revenue Growth | 90.4% | 92.1% | 92.8% | 69.6% | 60.7% |
| Gross Margin | 87.1% | 86.6% | 82.6% | 83.6% | 83.8% |
| EBITDA Margin | 7.1% | - | - | 17.0% | - |
| Net Margin | 4.2% | 20.0% | 241.7% | 9.7% | 21.3% |
| FCF Margin | -23.8% | - | - | -8.8% | - |
| Diluted EPS Growth | - | 325.0% | 12,050.0% | 300.0% | -85.6% |
Get the TGTX recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.